PhaseBio Pharmaceuticals, Inc. Positions for the Next Stage of Development by Bringing on Board Industry Veteran, Jonathan Mow as Chief Business Officer

MALVERN, Pa.--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc, a privately held, clinical-stage biotechnology company developing novel drugs to treat metabolic and cardiovascular diseases, announced today that Jonathan P. Mow has been appointed Chief Business Officer. Mr. Mow has more than 20 years of experience in business development and commercial operations, most recently with Amylin Pharmaceuticals, where he implemented the strategy that resulted in Amylin’s $7 billion acquisition by Bristol-Myers Squibb and Astra Zeneca. “PhaseBio has continued to move multiple products into the clinic. We are now ready to drive the strategic plans to bring these important advances to patients and Jonathan’s extensive commercial planning and deal making experience will position PhaseBio for significant growth,” said Christopher Prior, Ph.D., CEO of PhaseBio.